RAPID BREATH DETECTION OF LUNG CANCER

ISense医疗公司(IMC)传感器系统从呼气中检测肺癌信号的灵敏度将得到增强和演示，一个新的呼气收集设备将完成，并将完成对克利夫兰临床基金会(CCF)对8000名肺癌患者和对照组进行的ELDDA研究的修改方案。第一代非侵入性、廉价和快速的LUNF癌检测方法已经在CCF进行了测试，检测的特异性和选择性都在80年代。下一代传感器阵列包括嵌入纳米孔溶胶-凝胶基质中的光学指示器，现在对一系列肺癌呼吸标志物的敏感度提高了100倍，提高了已被证明在肺癌检测中有效的乳房传感器技术的敏感度。已批准的CCF方案将被改进，以评估特定的声称，即在不确定的肺部CT和IMC呼气测试后，肺癌诊断的假阳性降低了200%以上。此外，由于肺癌的呼吸信号来自活跃的肿瘤代谢，该方案将被调整以检验IMC呼吸休息代表着对化疗效果的快速和低成本评估的假设。

The sensitivity of iSense Medical Corp (IMC) sensor system for the detection of a lung cancer signature from breath will be enhanced and demonstrated, a new breath collection device completed and a modification of the Cleveland Clinic Foundation (CCF) protocol for the ELDDA study of 8000 lung cancer patients and controls will be completed. The first generation of this non-invasive, inexpensice and rapid assay for the presence of lunf cancer has already been tested at CCF wwith specificity and selectivity of detection in the 80s. The next generation of this sensor array,comprising optical indicators embedded in a nanoporous sol-gel matrix is now>100x more sensitive to a range of lung cancer breath markers, enhancing sensitivty for a breast sensor technology already proven effective in lung cancer detection. The approved CCF protocol will be refined to assess the specific claim that following an indeterminate lung CT witht he IMC breath test reduces lung cancer diagnosis false positives over 200%. Further, as lung cancer breath signature arises from active tumor metabolism, the protocol will be adapted to test the hypothesis that the IMC breath rest represents a rapid and low-cost assessment for the efficacy of chemotherapy.